Related Experiment Video

Updated: Aug 4, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K

The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma

Lea Jessica Albrecht1, Elisabeth Livingstone1, Lisa Zimmer1

  • 1Department of Dermatology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Current Oncology Reports
|April 2, 2023
PubMed
Abstract

Insights

A new combination therapy for advanced melanoma, relatlimab plus nivolumab, shows improved progression-free survival with fewer side effects than current treatments. Further research is needed to confirm overall survival benefits.

Area of Science:

  • Immunotherapy
  • Oncology
  • Melanoma Research

Background:

  • Dual immune checkpoint inhibition (ipilimumab plus nivolumab) is effective for advanced melanoma but highly toxic.
  • There is a need for more tolerable yet effective melanoma treatments.

Purpose of the Study:

  • To evaluate relatlimab (a LAG-3 blocking antibody) in combination with nivolumab for advanced melanoma.
  • To assess the efficacy and safety of this new combination compared to nivolumab monotherapy.

Main Methods:

  • Phase 2/3 randomized, double-blind trial (RELATIVITY-047).
  • Compared progression-free survival (PFS) and overall survival (OS) in treatment-naive advanced melanoma patients.

Main Results:

  • Significantly improved PFS with relatlimab plus nivolumab versus nivolumab monotherapy.
  • More favorable safety profile compared to ipilimumab plus nivolumab.
  • No significant difference in OS demonstrated yet between the combination and nivolumab monotherapy.

Conclusions:

  • Relatlimab plus nivolumab offers a new, less toxic treatment option for advanced melanoma, improving PFS.
  • Regulatory approvals expand melanoma treatment choices, necessitating re-evaluation of treatment standards.
  • Ongoing evaluation is crucial to determine long-term survival benefits and optimal clinical sequencing.
Keywords:
Dual checkpoint inhibitionLAG-3 blocking antibodyMelanomaOvercoming anti-PD-1 resistanceRelatlimab plus nivolumabT-cell exhaustion

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
598
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
459
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
216